New drug combo targets tough cancers in early trial

NCT ID NCT05661201

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase study tests the safety of combining an experimental drug called NEROFE with a standard chemotherapy, doxorubicin, in people with advanced solid tumors that have a KRAS mutation and express ST2. The trial aims to find the best dose and schedule for the combination. About 24 participants whose cancers have progressed after standard treatments will receive weekly infusions of both drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NEROFE and doxorubicin (chemotherapy)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced KRAS-mutated cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 24 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS MUTATION-RELATED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS MUTATION-RELATED TUMORS SOLID TUMOR

Contacts and locations

Locations

Georgetown Lombardi Comprehensive Cancer Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.